Literature DB >> 23885216

Chromosome X-encoded Cancer/Testis antigens are less frequently expressed in non-seminomatous germ cell tumors than in seminomas.

Yao-Tseng Chen1, Dengfeng Cao, Rita Chiu, Peishan Lee.   

Abstract

Cancer/Testis (CT) antigens are normally only expressed in germ cells and yet are aberrantly activated in a wide variety of human cancers. Most chromosome X-encoded CT antigens (CT-X) show restricted expression in pre-meiotic germ cells in adult testis, except for the expression of SPANX in post-meiotic germ cells. In the present study, the expression of eight CT-X antigens (MAGE-A, NY-ESO-1, GAGE, MAGE-C1/CT7, MAGE-C2/CT10, CT45, SAGE1, and SPANX) in non-seminomatous germ cell tumors was evaluated immunohistochemically, including 24 embryonal carcinomas, 20 yolk sac tumors, 9 teratomas, and 3 choriocarcinomas, and the results were compared to our previous study of 77 classic seminomas and 2 spermatocytic seminomas. SPANX was not detected in any germ cell tumors tested. Spermatocytic seminoma showed strong expression of all CT-X antigens tested (except SPANX), reflecting their origin from adult CT-Xpositive pre-meiotic germ cells. Classic seminomas, originating from prenatal gonocytes, showed widely variable frequency of CT-X antigen expression, ranging from > 80% (CT7, CT10, CT45, and GAGE), 63% (MAGE-A), 18% (NY-ESO-1) to only 4% (SAGE1). In comparison, non-seminomatous germ cell tumors expressed CT-X antigens much less frequently and usually only in small subsets of tumor cells. Intratubular germ cell neoplasia (ITGCN) were mostly CT-X-negative, even in CT-X positive classic seminomas. These findings indicate that CT-X antigens are not expressed in the fetal precursor cells for germ cell tumors, and their expression likely reflects germ cell differentiation of the neoplastic cells (in seminomas) or aberrant gene activation as cancer antigens (in non-seminomatous tumors).

Entities:  

Keywords:  CT-X antigen; germ cell tumors; tumor antigens

Mesh:

Substances:

Year:  2013        PMID: 23885216      PMCID: PMC3721301     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  39 in total

1.  Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.

Authors:  A A Jungbluth; Y T Chen; E Stockert; K J Busam; D Kolb; K Iversen; K Coplan; B Williamson; N Altorki; L J Old
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

2.  Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma.

Authors:  Yao-Tseng Chen; Rita Chiu; Peishan Lee; Debra Beneck; Boquan Jin; Lloyd J Old
Journal:  Hum Reprod       Date:  2011-10-20       Impact factor: 6.918

3.  MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors.

Authors:  F Aubry; A P Satie; N Rioux-Leclercq; E Rajpert-De Meyts; G C Spagnoli; P Chomez; O De Backer; B Jégou; M Samson
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

4.  Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen.

Authors:  T Ono; T Kurashige; N Harada; Y Noguchi; T Saika; N Niikawa; M Aoe; S Nakamura; T Higashi; A Hiraki; H Wada; H Kumon; L J Old; E Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Spermatid-specific expression of the novel X-linked gene product SPAN-X localized to the nucleus of human spermatozoa.

Authors:  V A Westbrook; A B Diekman; K L Klotz; V V Khole; C von Kap-Herr; W L Golden; R L Eddy; T B Shows; M H Stoler; C Y Lee; C J Flickinger; J C Herr
Journal:  Biol Reprod       Date:  2000-08       Impact factor: 4.285

6.  Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma.

Authors:  R Grobholz; C S Verbeke; C Schleger; K U Köhrmann; B Hein; G Wolf; U Bleyl; G C Spagnoli; K Coplan; D Kolb; K Iversen; A A Jungbluth
Journal:  Urol Res       Date:  2000-12

7.  Reactivity of germ cell maturation stage-specific markers in spermatocytic seminoma: diagnostic and etiological implications.

Authors:  H Stoop; R van Gurp; R de Krijger; A Geurts van Kessel; B Köberle; W Oosterhuis; L Looijenga
Journal:  Lab Invest       Date:  2001-07       Impact factor: 5.662

8.  Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.

Authors:  T Yuasa; K Okamoto; T Kawakami; M Mishina; O Ogawa; Y Okada
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450

Review 9.  Cancer/testis (CT) antigens: potential targets for immunotherapy.

Authors:  Otavia L Caballero; Yao-Tseng Chen
Journal:  Cancer Sci       Date:  2009-08-01       Impact factor: 6.716

10.  The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ.

Authors:  Anne-Pascale Satie; Ewa Rajpert-De Meyts; Giulio C Spagnoli; Sébastien Henno; Laurence Olivo; Grete Krag Jacobsen; Nathalie Rioux-Leclercq; Bernard Jégou; Michel Samson
Journal:  Lab Invest       Date:  2002-06       Impact factor: 5.662

View more
  3 in total

1.  Cancer testis antigen expression in testicular germ cell tumors and in intratubular germ cell neoplasia.

Authors:  Yao-Tseng Chen
Journal:  Mod Pathol       Date:  2015-05       Impact factor: 7.842

2.  Intratubular germ cell neoplasia of the human testis: heterogeneous protein expression and relation to invasive potential.

Authors:  Philippa Tk Saunders; Leendert Hj Looijenga; Rod T Mitchell; Maria Camacho-Moll; Joni Macdonald; Richard A Anderson; Christopher Jh Kelnar; Marie O'Donnell; Richard M Sharpe; Lee B Smith; Ken M Grigor; W Hamish B Wallace; Hans Stoop; Katja P Wolffenbuttel; Roland Donat
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

3.  Spontaneous CD4+ and CD8+ T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients.

Authors:  Hayden Pearce; Paul Hutton; Shalini Chaudhri; Emilio Porfiri; Prashant Patel; Richard Viney; Paul Moss
Journal:  Eur J Immunol       Date:  2017-06-26       Impact factor: 5.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.